Establishment of the Initial Protocol With Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization Associated With High Myopia:3 vs 1.
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Myopia
- Focus Therapeutic Use
- Acronyms BENEMCOR
- 27 Mar 2017 Planned End Date changed from 1 Jan 2016 to 1 Dec 2017.
- 27 Mar 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
- 23 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.